Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NextCure, Inc.NXTC · Entity 7461 | Sr VP, Dev. & Mfg. | January 30, 2026 | February 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NextCure, Inc.
Report date January 30, 2026 · Filed February 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.85 · Expires 2036-01-29 | Direct | 8,270 |
Reported balance
After 2026-01-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-30 · Grant · Acquired 8,270 · Balance 8,270 F1: One fourth of the option vests on January 30, 2027. The remainder vests in 36 monthly installments beginning on February 28, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: One fourth of the option vests on January 30, 2027. The remainder vests in 36 monthly installments beginning on February 28, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 30, 2026 Filed Feb 3, 2026 21:07 UTC | NextCure, Inc. NXTC · Entity 7461 | GrantEmployee Stock Option (Right to Buy) · Derivative | 8,270 | $0.00 Strike: $10.85 | $0.00 |
DisclosureSEC source: 0000905148-26-000479 · form4.xml · derivative · entry 1 Kundu Sourav · CIK 0001872985 · Sr VP, Dev. & Mfg. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,270 Underlying: Common Stock · 8,270 shares Expires 2036-01-29 F1 · derivative.exercise_date: One fourth of the option vests on January 30, 2027. The remainder vests in 36 monthly installments beginning on February 28, 2027. Read SEC document |
| January 31, 2025 Filed Feb 3, 2025 23:22 UTC | NextCure, Inc. NXTC · Entity 7461 | GrantEmployee Stock Option (Right to Buy) · Derivative | 66,125 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0000905148-25-000334 · form4.xml · derivative · entry 1 Kundu Sourav · CIK 0001872985 · Sr VP, Dev. & Mfg. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,125 Underlying: Common Stock · 66,125 shares Expires 2035-01-30 F1 · derivative.exercise_date: One fourth of the option vests on January 31, 2026. The remainder vests in 36 monthly installments beginning on February 28, 2026. Read SEC document |
| March 29, 2024 Filed Apr 2, 2024 20:40 UTC | NextCure, Inc. NXTC · Entity 7461 | GrantEmployee Stock Option (Right to Buy) · Derivative | 52,900 | $0.00 Strike: $2.23 | $0.00 |
DisclosureSEC source: 0000905148-24-001050 · form4.xml · derivative · entry 1 Kundu Sourav · CIK 0001872985 · Sr VP, Dev. & Mfg. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,900 Underlying: Common Stock · 52,900 shares Expires 2034-03-28 F1 · derivative.exercise_date: The option vests in full on the one year anniversary of the grant, March 29, 2025. Read SEC document |
| January 31, 2024 Filed Feb 1, 2024 21:43 UTC | NextCure, Inc. NXTC · Entity 7461 | GrantEmployee Stock Option (Right to Buy) · Derivative | 66,125 | $0.00 Strike: $1.22 | $0.00 |
DisclosureSEC source: 0000905148-24-000391 · form4.xml · derivative · entry 1 Kundu Sourav · CIK 0001872985 · Sr VP, Dev. & Mfg. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,125 Underlying: Common Stock · 66,125 shares Expires 2034-01-30 F1 · derivative.exercise_date: One fourth of the option vests on January 31, 2025. The remainder vests in 36 monthly installments beginning on February 28, 2025. Read SEC document |
| February 28, 2023 Filed Mar 1, 2023 23:02 UTC | NextCure, Inc. NXTC · Entity 7461 | GrantEmployee Stock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $1.55 | $0.00 |
DisclosureSEC source: 0001140361-23-009493 · form4.xml · derivative · entry 1 Kundu Sourav · CIK 0001872985 · Sr VP, Dev. & Mfg. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2033-02-27 F1 · derivative.exercise_date: One fourth of the option vests on February 28, 2024. The remainder vests in 36 monthly installments beginning on March 28, 2024. Read SEC document |
| January 31, 2022 Filed Feb 2, 2022 21:19 UTC | NextCure, Inc. NXTC · Entity 7461 | GrantEmployee Stock Option (Right to Buy) · Derivative | 58,700 | $0.00 Strike: $5.57 | $0.00 |
DisclosureSEC source: 0000905148-22-000161 · form4.xml · derivative · entry 1 Kundu Sourav · CIK 0001872985 · Sr VP, Dev. & Mfg. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,700 Underlying: Common Stock · 58,700 shares Expires 2032-01-30 F1 · derivative.exercise_date: One fourth of the option vests on January 31, 2023. The remainder vests in 36 monthly installments beginning on February 28, 2023. Read SEC document |
| July 15, 2021 Filed Jul 19, 2021 20:07 UTC | NextCure, Inc. NXTC · Entity 7461 | GrantEmployee Stock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $7.89 | $0.00 |
DisclosureSEC source: 0001567619-21-013638 · doc1.xml · derivative · entry 1 Kundu Sourav · CIK 0001872985 · Sr VP, Dev. & Mfg. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2031-07-05 F1 · derivative.exercise_date: One fourth of the option vests on July 6, 2022. The remainder vests in 36 monthly installments beginning on August 6, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.